Divi's Laboratories Limited (DIVISLAB) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally.
Total Assets Chart for Divi's Laboratories Limited
Divi's Laboratories Limited (DIVISLAB) total assets for FY2026 were INR 200.3B, a 18.2% change from FY2025. Divi's Laboratories Limited's total assets grew from INR 4.5B in 2005 to INR 200.3B in 2026 (4309.7% over 21 years). Total assets compound annual growth rate: 5-year CAGR of 13.2%, 10-year CAGR of 15.1%, 20-year CAGR of 18.7%.
Total Assets (Indian Rupees)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ₹2.41T
- Implied Share Price
- ₹9060.00
- Enterprise Value
- ₹2.36T
- Revenue (TTM)
- ₹112.30B
- EBITDA
- ₹39.65B
- Profit Margin
- 26.05%
- Trailing P/E
- 93.82
- Forward P/E
- 19.57
- Price/Book (MRQ)
- 14.29
- Price/Sales (TTM)
- 21.42
- EV/EBITDA
- 61.01
- EV/Revenue
- 22.56
- Dividend Yield
- 0.00%
- Book Value
- ₹631.37
- Free Cash Flow (FY2026)
- ₹4.97B
- Free Cash Flow Yield
- 0.21%
Snapshot as of 27th August 2026 — not point-in-time controlled, may lag the live market by a few days.